IRIDEX Corporation cannot accurately predict the impact to glaucoma probes and system sales that will result from the reimbursement changes of the five LCDs as customers and prospects evaluate their usage of probes and system purchases. Given this uncertainty, guidance for 2023 has been withdrawn as the impact to Cyclo G6 system and probe sales is evaluated further.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.1 USD | -1.87% | -8.70% | -25.27% |
May. 24 | IRIDEX Corporation Appoints Patrick Mercer as Its President | CI |
May. 14 | IRIDEX Corporation Reports Earnings Results for the First Quarter Ended March 30, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.27% | 34.13M | |
+7.77% | 218B | |
+10.16% | 189B | |
+26.21% | 151B | |
+32.78% | 113B | |
+1.98% | 64.02B | |
+14.48% | 52.6B | |
+2.92% | 49.85B | |
-6.60% | 37.89B | |
-1.07% | 34.92B |
- Stock Market
- Equities
- IRIX Stock
- News IRIDEX Corporation
- IRIDEX Corporation Withdraws Previously Announced Guidance for 2023